Chin Chih-Chien, Yeh Chien-Yuh, Tang Reiping, Changchien Chung-Rong, Huang Wen-Shih, Wang Jeng-Yi
Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Int J Colorectal Dis. 2008 Aug;23(8):783-8. doi: 10.1007/s00384-008-0465-5. Epub 2008 Apr 26.
It remains controversial as to whether high ligation of the inferior mesenteric artery (IMA) should be performed during surgical treatment for sigmoid colon or rectal cancer. The purpose of this study is to attempt to clarify the extent of the oncologic benefit of high ligation of the IMA.
From January 1995 to July 2001, a total of 1,389 patients underwent high ligation of the IMA; 387 patients featured non-disseminated sigmoid colon cancer and 1,002 patients had rectal cancer. Pathology of the primary tumors, IMA nodes, and clinical outcome were reviewed.
Forty-three patients (3.1%) revealed IMA node metastasis. Of these 43 patients, 29 (67.4%) featured tumor recurrences/metastases. After a minimum 5-year follow-up, 11 of these 43 patients (25.6%) were alive and disease free. Of these 43 patients, the 5-year disease-free survival rate for patients featuring sigmoid cancer was 50% and for patients with rectal cancer 13.8%. The beneficial rate of high ligation of the IMA for non-disseminated sigmoid colon cancer and rectal cancer was 0.8%, for non-disseminated sigmoid colon cancer 1.8%, and for non-disseminated rectal cancer, the rate was only 0.4%. The rates of IMA metastasis in patients with T stage tumors were 0% (pT1), 1.0% (pT2), 2.6% (pT3), and 4.3% (pT4).
Although patients afflicted with IMA node metastasis revealed a rather high incidence of tumor recurrence/metastasis, 25.6% of these patients remained disease free following IMA node dissection after a minimum 5-year follow-up. We consider that IMA node dissection is more beneficial in patients with non-disseminated sigmoid pT4 tumor.
在乙状结肠癌或直肠癌的外科治疗中,肠系膜下动脉(IMA)高位结扎是否必要仍存在争议。本研究旨在明确IMA高位结扎在肿瘤学方面的获益程度。
1995年1月至2001年7月,共有1389例患者接受了IMA高位结扎;其中387例为非播散性乙状结肠癌患者,1002例为直肠癌患者。对原发肿瘤、IMA淋巴结的病理及临床结果进行了回顾。
43例患者(3.1%)出现IMA淋巴结转移。在这43例患者中,29例(67.4%)出现肿瘤复发/转移。经过至少5年的随访,这43例患者中有11例(25.6%)存活且无疾病。在这43例患者中,乙状结肠癌患者的5年无病生存率为50%,直肠癌患者为13.8%。IMA高位结扎对非播散性乙状结肠癌和直肠癌的获益率为0.8%,对非播散性乙状结肠癌为1.8%,对非播散性直肠癌仅为0.4%。T分期肿瘤患者的IMA转移率分别为0%(pT1)、1.0%(pT2)、2.6%(pT3)和4.3%(pT4)。
尽管患有IMA淋巴结转移的患者肿瘤复发/转移发生率较高,但经过至少5年的随访,这些患者中有25.6%在IMA淋巴结清扫后仍无疾病。我们认为IMA淋巴结清扫对非播散性乙状结肠pT4肿瘤患者更有益。